title: Anti-angiogenic and anti-inflammatory effects of SERPINA3K on corneal injury.
abstract: SERPINA3K is a member of the serine proteinase inhibitor (SERPIN) family. Here we evaluated the therapeutic effects of SERPINA3K on neovascularization and inflammation in a rat cornea alkali burn model that is commonly employed to study corneal wounding. Topical treatment of the injured rat cornea with SERPINA3K (20 µg/eye/day) for 7 days significantly decreased the neovascular area, compared with the groups treated with BSA or PBS. The SERPINA3K treatment also ameliorated the corneal inflammation as evaluated by the inflammatory index. Furthermore, SERPINA3K enhanced the recovery of corneal epithelium after the alkali injury. Toward the mechanism of action, SERPINA3K down-regulated the expression of the pro-angiogenic and pro-inflammatory factors, vascular endothelial growth factor and tumor necrosis factor-α and up-regulated the expression of the anti-angiogenic factor, pigment epithelium-derived factor. SERPINA3K specifically inhibited growth of vascular endothelial cells. Meanwhile, SERPINA3K significantly up-regulated the expression of EGFR in the corneal epithelium. These findings suggest that SERPINA3K has therapeutic potential for corneal inflammation and NV.
authors.affiliation: Eye Institute of Xiamen University, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Xiamen, China.
authors.forename: Xiaochen
authors.initials: X
authors.lastname: Liu
authors.forename: Zhirong
authors.initials: Z
authors.lastname: Lin
authors.forename: Tong
authors.initials: T
authors.lastname: Zhou
authors.forename: Ronrong
authors.initials: R
authors.lastname: Zong
authors.forename: Hui
authors.initials: H
authors.lastname: He
authors.forename: Zhen
authors.initials: Z
authors.lastname: Liu
authors.forename: Jian-xing
authors.initials: JX
authors.lastname: Ma
authors.forename: Zuguo
authors.initials: Z
authors.lastname: Liu
authors.forename: Yueping
authors.initials: Y
authors.lastname: Zhou
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D043924:Angiogenesis Modulating Agents / Q000032:analysis; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology; D003315:Cornea / Q000098:blood supply / Q000473:pathology; D065306:Corneal Injuries; D016510:Corneal Neovascularization / Q000188:drug therapy*; D005126:Eye Burns / Q000139:chemically induced; D005786:Gene Expression Regulation / Q000187:drug effects; D007249:Inflammation / Q000188:drug therapy*; D018836:Inflammation Mediators / Q000032:analysis; D023421:Models, Animal; D051381:Rats; D015843:Serpins / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D043924:Angiogenesis Modulating Agents; D000893:Anti-Inflammatory Agents; D018836:Inflammation Mediators; C050936:Serpina3c protein, rat; D015843:Serpins